Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Starch × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Gynecologic 1

Conditions

Gastrointestinal Toxicity 1

Interventions

Paclitaxel 68 Carboplatin 66 Cisplatin 36 pembrolizumab 34 liposomal doxorubicin 23 Gemcitabine 23 Cyclophosphamide 23 Topotecan 22 Bevacizumab 20 Taxes 14 Docetaxel 13 niraparib 12 Nivolumab 12 olaparib 10 fludarabine 10 Doxorubicin 9 Surveys and Questionnaires 8 Radiotherapy 8 Oxaliplatin 8 aldesleukin 7 Filgrastim 7 rucaparib 6 oregovomab 6 fludarabine phosphate 6 durvalumab 6 avelumab 6 Interleukin-2 6 Hyperthermic Intraperitoneal Chemotherapy 6 Fluorodeoxyglucose F18 6 Cytoreduction Surgical Procedures 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02351089 2020-03-05

ProRad

Probi AB

Phase NA Terminated

GastrointestinalGynecologic

Gastrointestinal Toxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡